Eli Lilly Stock Declines Amid Disappointment in Obesity Pill Trials
Eli Lilly's stock (LLY) continues to decline as investor enthusiasm for its obesity medication wanes, reflecting changing market dynamics and investor sentiment.
Tag
Lly
All articles tagged with #lly
"Viking Therapeutics Leads Weight-Loss Drug Fervor with Stock Surge"
Eli Lilly's stock is on the rise as it forms a flat base amidst increasing competition in the weight-loss drug space, particularly with Viking Therapeutics' promising test results for its experimental pill. Despite this, analysts remain optimistic about Lilly's weight-loss drugs, Zepbound and Wegovy, with expectations of significant sales growth. The company is also developing new pills targeting GLP-1 and GIP, aiming for stronger weight loss. Eli Lilly stock has shown strength in technical and fundamental measures, remaining above its 50-day moving average and boasting a strong Relative Strength Rating and Composite Rating.